180 Life Sciences Corp.
Index- P/E- EPS (ttm)-7.72 Insider Own0.70% Shs Outstand2.24M Perf Week-1.79%
Market Cap8.25M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float1.41M Perf Month98.80%
Income-15.90M PEG- EPS next Q0.20 Inst Own15.30% Short Float / Ratio38.10% / 0.13 Perf Quarter-63.37%
Sales- P/S- EPS this Y2.00% Inst Trans- Short Interest0.54M Perf Half Y-84.86%
Book/sh13.31 P/B0.25 EPS next Y- ROA-30.40% Target Price80.00 Perf Year-93.55%
Cash/sh1.44 P/C2.29 EPS next 5Y- ROE-42.80% 52W Range1.18 - 71.40 Perf YTD-2.65%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-95.38% Beta0.67
Dividend %- Quick Ratio1.40 Sales past 5Y- Gross Margin- 52W Low179.66% ATR1.04
Employees7 Current Ratio1.40 Sales Q/Q- Oper. Margin- RSI (14)44.32 Volatility25.83% 31.76%
OptionableYes Debt/Eq0.02 EPS Q/Q-201.00% Profit Margin- Rel Volume0.08 Prev Close3.24
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume4.28M Price3.30
Recom2.50 SMA20-14.72% SMA50-37.59% SMA200-80.28% Volume357,648 Change1.85%
Sep-15-21Initiated Maxim Group Buy $11
Jan-25-23 08:45AM
Jan-17-23 08:00AM
Jan-05-23 08:30AM
Jan-04-23 08:30AM
Dec-29-22 08:30AM
08:00AM Loading…
Dec-23-22 08:00AM
Dec-20-22 02:11PM
Dec-16-22 09:00AM
Nov-30-22 05:00PM
Nov-21-22 08:30AM
Nov-15-22 12:37PM
Sep-26-22 08:30AM
Aug-22-22 08:30AM
Jul-27-22 08:30AM
08:00AM Loading…
Jul-21-22 08:00AM
Jul-18-22 08:30AM
Jun-22-22 04:05PM
Jun-14-22 04:15PM
May-31-22 08:30AM
May-02-22 08:00AM
Apr-29-22 06:32PM
Feb-17-22 08:30AM
Jan-31-22 08:00AM
Dec-28-21 11:00AM
Dec-15-21 08:15AM
Dec-12-21 06:06AM
Dec-10-21 05:15PM
Dec-06-21 08:15AM
Dec-01-21 02:45PM
02:26PM Loading…
Nov-22-21 08:30AM
Nov-18-21 08:15AM
Nov-03-21 12:06PM
Oct-26-21 08:30AM
Sep-30-21 08:30AM
Sep-20-21 08:00AM
Aug-30-21 08:30AM
Aug-24-21 08:30AM
Aug-19-21 09:00AM
Aug-02-21 08:00AM
Jul-29-21 08:00AM
Jul-28-21 08:15AM
Jul-20-21 08:00AM
Jul-12-21 09:51AM
Jul-07-21 08:00AM
Jun-28-21 08:15AM
Jun-10-21 09:12AM
Jun-01-21 08:00AM
May-28-21 08:00AM
May-21-21 04:45PM
Apr-20-21 08:00AM
Apr-19-21 05:00PM
Apr-14-21 08:15AM
Mar-26-21 08:30AM
Mar-25-21 08:30AM
Mar-24-21 08:30AM
Mar-08-21 01:30PM
Feb-24-21 04:00PM
Feb-19-21 09:00AM
Feb-17-21 12:00AM
Jan-11-21 08:00AM
Jan-05-21 02:50PM
Dec-03-20 11:08AM
Nov-24-20 10:00AM
Nov-23-20 08:30AM
Nov-17-20 08:00AM
Nov-10-20 11:46AM
1180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials that are man-made derivatives of CBD; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.